10:09 AM EST - Satellos Bioscience Inc. : Today announced that enrollment has been completed for BASECAMP, the company’s Phase 2 clinical trial evaluating forazapadin for the treatment of Duchenne muscular dystrophy in ambulatory boys seven to 10 years of age. Satellos Bioscience Inc.
shares T.MSCL are trading down $0.12 at $12.08.
